Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

BACKGROUND: Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asympto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Rathkopf, Dana E., Smith, Matthew R., de Bono, Johann S., Logothetis, Christopher J., Shore, Neal D., de Souza, Paul, Fizazi, Karim, Mulders, Peter F.A., Mainwaring, Paul, Hainsworth, John D., Beer, Tomasz M., North, Scott, Fradet, Yves, Van Poppel, Hendrik, Carles, Joan, Flaig, Thomas W., Efstathiou, Eleni, Yu, Evan Y., Higano, Celestia S., Taplin, Mary-Ellen, Griffin, Thomas W., Todd, Mary, Yu, Margaret, Park, Youn C., Kheoh, Thian, Small, Eric J., Scher, Howard I., Molina, Arturo, Ryan, Charles J., Saad, Fred
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418928/
https://ncbi.nlm.nih.gov/pubmed/24647231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2014.02.056
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados